Item VI definition

AI-Powered Contracts

Draft, Review & Redline at the Speed of AI

Item VI. PREPARATION TIME

Item VI. Payment to the Assignor on Funding Date: Item VII: Percentage Assigned: %

Examples of Item VI in a sentence

In addition to the rates set forth at Item VI of the Pricing Schedule, Requesting Carrier shall pay Ameritech (i) for any applicable charges or fees, if any, incident to the establishment or provision of the Resale Services requested by Requesting Carrier, including channel charges, initial non-recurring charges and construction charges and (ii) the applicable non-discounted end user common line charge as set forth in F.C.C. No. 2, Section 4.
In addition to the rates set forth at Item VI of the Pricing Schedule, Requesting Carrier shall pay Ameritech (i) for any applicable charges or fees, if any, incident to the establishment or provision of the Resale Services requested by Requesting Carrier, including channel charges, initial non-recurring charges and construction charges and (ii) the applicable non- discounted end user common line charge as set forth in F.C.C. No. 2, Section 4.
No later than 90 days after the conclusion of Phase I and annually thereafter no later than September 30 of each year until the monitoring of this Agreement is closed, the District will provide OCR with the dates and locations that informational programs were held pursuant to Item VI of this Agreement.
Should you disagree with any amendments, please exercise your right to request that NCHU discontinue to collect, process or use your personal data according to Item VI of Article I.
No later than 90 days after the conclusion of Phase I, the District will submit to OCR for review a description with informational programs developed by the District in accordance with Item VI of this Agreement, including any translated materials.

More Definitions of Item VI

Item VI. This Item needs to be read by the investor and signed in acknowledgment.

Item VI. Payment to the Assignor on Funding Date: Item VII: Percentage Assigned: ___% (Expressed as a percentage of the total aggregate Commitments of the Bank Group, carry out to 10 decimal places; upon effectiveness of the Assignment as provide in the Credit Agreement, this will constitute the Assignee’s “Pro Rata Share” Item VIII: Revised Percentage of the Assignor: ___% (carry out to 10 decimal places; upon effectiveness of the Assignment as provided in the Credit Agreement, this will constitute the Assignor’s “Pro Rata Share”) Bank: Initial Commitment: Percentage: U.S. Bank $ 35,000,000 23.333333333333 % J▇ ▇▇▇▇▇▇ C▇▇▇▇ $ 22,500,000 15.000000000000 % W▇▇▇▇ Fargo $ 22,500,000 15.000000000000 % H▇▇▇▇▇ Bank $ 15,000,000 10.000000000000 % Key Bank $ 15,000,000 10.000000000000 % Bank of America $ 10,000,000 6.666666666667 % Union Bank of California $ 15,000,000 10.000000000000 % Bank Hapoalim $ 7,500,000 5.000000000000 % Bank of the West $ 7,500,000 5.000000000000 % % Total: $ 150,000,000 100.000000000000 %

Item VI. Payment to the Assignor on Funding Date: Item VII: Percentage Assigned: ___% (Expressed as a percentage of the total aggregate Commitments of the Bank Group, carry out to 10 decimal places; upon effectiveness of the Assignment as provide in the Credit Agreement, this will constitute the Assignee’s “Pro Rata Share” Item VIII: Revised Percentage of the Assignor: ___% (carry out to 10 decimal places; upon effectiveness of the Assignment as provided in the Credit Agreement, this will constitute the Assignor’s “Pro Rata Share”) Bank: Initial Commitment: Percentage: U.S. Bank $ 40,000,000 40.00000 % J▇ ▇▇▇▇▇▇ Chase $ 25,000,000 25.00000 % W▇▇▇▇ Fargo $ 25,000,000 25.00000 % Bank Hapoalim $ 10,000,000 10.00000 % Total: $ 100,000,000 100.00000 %

Item VI. The USA Freedom Act requires us to collect information on the sources of funds. Please complete section 1, add the documents requested in section 2 only if funds did not come from an approved country (U.S. is approved), and complete section 3. Item VII: You must thoroughly complete the Suitability Questionnaire, in order for the Company and the Managing Dealer to make a determination whether this is a suitable investment for you. Item VIII: You and must sign and date here. Review and complete the Investor Representation & Suitability Questionnaire and deliver it to the email or address below along with payment for your investment. Email: ▇▇▇▇▇▇▇▇▇@▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇ Subject: Asset Entities Inc. – [Investor Name] Address: Boustead Securities, LLC ▇ ▇▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇ ▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇ Bank Name: Banc of California Bank Address: ▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇, ▇▇ ▇▇▇▇▇ SWIFT Code: ▇▇▇▇▇▇▇▇ Routing #: ▇▇▇▇▇▇▇▇▇ Account Name: ▇▇▇▇▇▇ Securities Inc. Account #: 2030650369 REF / Notes: Asset Entities Inc. – [Investor Name] Email: ▇▇▇▇▇▇▇▇▇@▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇ Phone: (▇▇▇) ▇▇▇-▇▇▇▇ Please read all instructions of this Investor Representation and Suitability Questionnaire (this “Questionnaire”) carefully before filling out this Questionnaire. This is a legally binding document. If you need assistance, please call ▇▇▇-▇▇▇-▇▇▇▇ or by email at ▇▇▇▇▇▇▇▇▇@▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇.

Item VI. The USA Freedom Act requires us to collect information on the sources of funds. Please complete section 1, add the documents requested in section 2 only if funds did not come from an approved country (U.S. is approved), and complete section 3. Item VII: You must thoroughly complete the Suitability Questionnaire in order for the Company and the Managing Dealer to make a determination whether this is a suitable investment for you. Item VIII: You must sign and date here. If you prefer to send a wire transfer instead of a check, please mail or deliver your completed Investor Representation and Suitability Questionnaire to the address above and send the wire transfer using these instructions: FOR VALUE RECEIVED, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (“Shuttle Pharma” or the “Maker”), hereby promises to pay to the order of________________ (the “Subscriber”), or its registered assigns (together with the Subscriber, the “Holder”), the amount set out above as the Original Principal Amount, as reduced pursuant to the terms hereof pursuant to redemption, conversion or otherwise (the “Principal”), when due, whether upon the Maturity Date (as defined below), acceleration, redemption or otherwise (in each case in accordance with the terms hereof) and to pay interest (“Interest”) on any outstanding Principal at the applicable Interest Rate from the date set out above as the Issuance Date (the “Issuance Date”) until the same becomes due and payable, upon the Maturity Date or acceleration, conversion, redemption or otherwise (in each case in accordance with the terms hereof).

Item VI. The USA Freedom Act requires us to collect information on the sources of funds. Please complete section 1, add the documents requested in section 2 only if funds did not come from an approved country (U.S. is approved), and complete section 3. Item VII: You must thoroughly complete the Suitability Questionnaire in order for the Company and the Managing Dealer to make a determination whether this is a suitable investment for you. Item VIII: You must sign and date here. If you prefer to send a wire transfer instead of a check, please mail or deliver your completed Investor Representation and Suitability Questionnaire to the address above and send the wire transfer using these instructions: Email: o▇▇▇▇▇▇▇▇@▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇ Phone: 9▇▇-▇▇▇-▇▇▇▇ This Term Sheet Summary (the “Term Sheet”) summarizes the terms on which you and other qualified accredited investors (the “Investors”) are invited to make an investment (the “Investment”) in Shuttle Pharmaceuticals Holdings, Inc. a Delaware corporation. This Term Sheet is merely a summary of the terms and provisions of the Subscription Agreement (the “Subscription Agreement”), the form of which will be provided to you. Accordingly, this Term Sheet is qualified in its entirety by reference, and is subject in all instances, to the terms and provisions of the Subscription Agreement. You are advised to carefully review the terms and provisions of the Subscription Agreement, as well as the risk factors attached thereto, before making a decision concerning the Investment.